Cargando…

Longitudinal analysis of safety and medication adherence of patients in the Fingolimod patient support program: a real-world observational study

The Fingolimod Patient Support Program (F-PSP) is an interprofessional specialty pharmacy service designed to ensure responsible use of fingolimod by promoting patient safety and medication adherence. This study aims to evaluate the safety and medication adherence of patients who joined the F-PSP be...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bourdin, Aline, Schneider, Marie Paule, Locatelli, Isabella, Schluep, Myriam, Bugnon, Olivier, Berger, Jérôme
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7892872/ https://www.ncbi.nlm.nih.gov/pubmed/33603005 http://dx.doi.org/10.1038/s41598-021-83220-1

Ejemplares similares

Satisfaction and experiences of patients taking fingolimod and involved in a pharmacy-based patient support program in Switzerland — a qualitative study
por: Bourdin, Aline, et al.
Publicado: (2020)

Effectiveness of an Interprofessional Program (Siscare) for Supporting Patients With Type 2 Diabetes
por: Bawab, Noura, et al.
Publicado: (2023)

Interdisciplinary Medication Adherence Program: The Example of a University Community Pharmacy in Switzerland
por: Lelubre, Mélanie, et al.
Publicado: (2015)

Home-based subcutaneous immunoglobulin for chronic inflammatory demyelinating polyneuropathy patients: A Swiss cost-minimization analysis
por: Perraudin, Clémence, et al.
Publicado: (2020)

A Novel Approach to Better Characterize Medication Adherence in Oral Anticancer Treatments
por: Schneider, Marie Paule, et al.
Publicado: (2019)

The VZV/IE63-specific T cell response prevents herpes zoster in fingolimod-treated patients
por: Mathias, Amandine, et al.
Publicado: (2016)

Impaired T-cell migration to the CNS under fingolimod and dimethyl fumarate
por: Mathias, Amandine, et al.
Publicado: (2017)

The real-world patient experience of fingolimod and dimethyl fumarate for multiple sclerosis
por: Wicks, Paul, et al.
Publicado: (2016)

Real World Lab Data: Patterns of Lymphocyte Counts in Fingolimod Treated Patients
por: Kaufmann, Maxi, et al.
Publicado: (2018)

Implementation of an interprofessional medication adherence program for chronic patients in community pharmacies: how much does it cost for the provider?
por: Perraudin, Clemence, et al.
Publicado: (2019)

Fingolimod Real World Experience: Efficacy and Safety in Clinical Practice
por: Fonseca, Joaquim
Publicado: (2015)

Implementation study of an interprofessional medication adherence program for HIV patients in Switzerland: quantitative and qualitative implementation results
por: Lelubre, Mélanie, et al.
Publicado: (2018)

Implementation of an interprofessional medication adherence program for HIV patients: description of the process using the framework for the implementation of services in pharmacy
por: Lelubre, Mélanie, et al.
Publicado: (2018)

Determination of Seminal Concentration of Fingolimod and Fingolimod‐Phosphate in Multiple Sclerosis Patients Receiving Chronic Treatment With Fingolimod
por: David, Olivier J., et al.
Publicado: (2017)

Real-world experience of fingolimod in patients with multiple sclerosis (MS Fine): An observational study in the UK
por: Mazibrada, Gordon, et al.
Publicado: (2018)

The real-world effectiveness and safety of fingolimod in relapsing-remitting multiple sclerosis patients: An observational study
por: Izquierdo, Guillermo, et al.
Publicado: (2017)

Effectiveness of fingolimod in real-world relapsing-remitting multiple sclerosis Italian patients: the GENIUS study
por: Comi, Giancarlo, et al.
Publicado: (2020)

Long-term safety and real-world effectiveness of fingolimod in relapsing multiple sclerosis
por: Druart, Charlotte, et al.
Publicado: (2017)

Spanish real-world experience with fingolimod in relapsing-remitting multiple sclerosis patients: MS NEXT study
por: Barrero, Francisco, et al.
Publicado: (2020)

REALMS study: real-world effectiveness and safety of fingolimod in patients with relapsing-remitting multiple sclerosis in Portugal
por: Batista, S., et al.
Publicado: (2020)

Descriptive Analysis of Real-World Data on Fingolimod Long-Term Treatment of Young Adult RRMS Patients
por: Ziemssen, Tjalf, et al.
Publicado: (2021)

Real-world persistence and benefit–risk profile of fingolimod over 36 months in Germany
por: Ziemssen, Tjalf, et al.
Publicado: (2019)

Long-term real-world effectiveness and safety of fingolimod over 5 years in Germany
por: Ziemssen, Tjalf, et al.
Publicado: (2022)

The Presence of Human Immunodeficiency Virus-Associated Neurocognitive Disorders Is Associated With a Lower Adherence to Combined Antiretroviral Treatment
por: Kamal, Susan, et al.
Publicado: (2017)

Safety and Temporal Pattern of the Lymphocyte Count During Fingolimod Therapy in Patients With Multiple Sclerosis: Real-World Korean Experience
por: Huh, So-Young, et al.
Publicado: (2022)

Real-World Outcomes in Fingolimod-Treated Patients with Multiple Sclerosis in the Czech Republic: Results from the 12-Month GOLEMS Study
por: Tichá, Veronika, et al.
Publicado: (2016)

Long-Term Effectiveness, Safety and Tolerability of Fingolimod in Patients with Multiple Sclerosis in Real-World Treatment Settings in France: The VIRGILE Study
por: Papeix, Caroline, et al.
Publicado: (2022)

Treatment satisfaction and quality of life in patients treated with fingolimod
por: Mékiès, Claude, et al.
Publicado: (2018)

Real-world effectiveness of dimethyl fumarate versus fingolimod in a cohort of patients with multiple sclerosis using standardized, quantitative outcome metrics
por: Hersh, Carrie M, et al.
Publicado: (2022)

The effectiveness of interferon beta versus glatiramer acetate and natalizumab versus fingolimod in a Polish real-world population
por: Kapica-Topczewska, Katarzyna, et al.
Publicado: (2019)

Interprofessional Medication Adherence Program for Patients With Diabetic Kidney Disease: Protocol for a Randomized Controlled and Qualitative Study (PANDIA-IRIS)
por: Bandiera, Carole, et al.
Publicado: (2021)

Real-world adherence to topical therapies in patients with moderate acne
por: Lam Hoai, Xuân-Lan, et al.
Publicado: (2021)

Modulation of Cardiac Autonomic Function by Fingolimod Initiation and Predictors for Fingolimod Induced Bradycardia in Patients with Multiple Sclerosis
por: Li, Kai, et al.
Publicado: (2017)

Real‐life long‐term effectiveness of fingolimod in Swiss patients with relapsing‐remitting multiple sclerosis
por: Zecca, C., et al.
Publicado: (2018)

Efficacy and Safety of Fingolimod in an Unselected Patient Population
por: Rasenack, Maria, et al.
Publicado: (2016)

COVID-19 Infection in Fingolimod- or Siponimod-Treated Patients: Case Series
por: Sullivan, Roseanne, et al.
Publicado: (2021)

Retrospective analysis of effectiveness of fingolimod in real life setting in Turkey (REFINE)
por: TUNCER, Aslı, et al.
Publicado: (2022)

Comparative Adherence Trajectories of Oral Fingolimod and Injectable Disease Modifying Agents in Multiple Sclerosis
por: Earla, Jagadeswara R, et al.
Publicado: (2020)

Medication adherence in Fabry patients treated with migalastat: Real world experience
por: Riccio, Eleonora, et al.
Publicado: (2023)

Progressive multifocal leukoencephalopathy after fingolimod treatment
por: Berger, Joseph R., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_8p551up4ii25gdl6kjrtlk2gru